𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer

✍ Scribed by Onder Tonyali, Ugur Coskun, Nur Sener, Mevlude Inanc, Tulay Akman, Berna Oksuzoglu, Nuriye Yildirim Ozdemir, Dogan Yazilitas, Mustafa Benekli, Aytug Uner, Deniz Yamac, Umut Demirci, Ramazan Yildiz, Halit Karaca, Olcun Umit Unal, et al

Book ID
118785487
Publisher
Springer-Verlag
Year
2012
Tongue
English
Weight
240 KB
Volume
138
Category
Article
ISSN
1432-1335

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cost-effectiveness analysis of trastuzum
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 209 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t